Table 2.
Double-blind randomised controlled trials for entecavir: 48-week results
Trial | HBeAg | Endpoint | Entecavir 0.5 mg OD (%) | Lamivudine 100 mg OD (%) |
---|---|---|---|---|
ETV-022 [57] | Positive | HBV DNA
<300 copies/mL |
236/354 (67%) | 129/355 (36%) |
ETV-027 [58] | Negative | HBV DNA
<300 copies/mL |
293/325 (90%) | 225/313 (72%) |
P values for all results in table are <0.001. More than 80% of patients in both studies were treatment naïve, with similar proportions in both arms